MOTS-c: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any decision involving a substance discussed here. Nothing below describes a protocol, and no outcome described in animal or cell research should be assumed to transfer to people.

How this course is organised

Six modules move from definition to mechanism to reported outcomes, then to adverse events, pharmacokinetics and regulatory status. Every module closes with the limits of the evidence that module rests on, because the MOTS-c literature is overwhelmingly preclinical and the gap between a mouse endpoint and a human one is the single most important thing to carry out of this page.

Module 1 — What MOTS-c is and how it has been studied

Definition and class. MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a short peptide of 16 amino acids. It belongs to a class called mitochondrial-derived peptides (MDPs) — peptides encoded not in nuclear DNA but within the mitochondrial genome itself. A 2023 review in Frontiers in Endocrinology described MOTS-c as an MDP encoded in the mitochondrial 12S rRNA region and discussed it as a candidate for therapeutic exploitation across metabolic and age-related conditions (PMID 36761202).

Origin. The founding paper appeared in Cell Metabolism in 2015, where researchers identified MOTS-c as a mitochondrial-derived peptide and reported that it promoted metabolic homeostasis and reduced obesity and insulin resistance in mouse models (PMID 25738459). That paper set the template for nearly all subsequent work: synthetic peptide administered to cells or rodents, with metabolic or tissue endpoints measured.

Forms encountered in research. Studies typically use chemically synthesised MOTS-c matching the endogenous sequence, delivered by intraperitoneal or intravenous injection in animals or added directly to culture medium in vitro. Some studies instead manipulate endogenous MOTS-c — for example, a 2024 paper in Journal of Agricultural and Food Chemistry reported that pyrroloquinoline quinone alleviated mitochondrial damage in radiation-induced lung injury in a MOTS-c-dependent manner, using MOTS-c as a mechanistic node rather than an administered drug (PMID 39259217).

Limits of the evidence in Module 1

Definitions are settled; clinical identity is not. The literature characterises MOTS-c as an endogenous signalling peptide, but there is no standardised pharmaceutical formulation, no agreed reference preparation, and no approved product. Descriptions of "forms" reflect what laboratories synthesised for experiments, not commercial products with verified content.

Module 2 — Mechanism as described in the literature

Metabolic signalling. The original Cell Metabolism work reported that MOTS-c acted on the folate–methionine cycle and influenced AMPK signalling, with downstream effects on glucose handling in mouse tissue (PMID 25738459). The 2023 review summarised mechanistic threads across the field, including AMPK activation, nuclear translocation under metabolic stress, and regulation of stress-response gene expression (PMID 36761202).

Direct protein binding. More recent work has moved toward identifying binding partners. A 2024 iScience study reported that MOTS-c modulated skeletal muscle function by directly binding and activating casein kinase 2 (CK2) (PMID 39559755). A 2025 Redox Biology paper described a different route, reporting that MOTS-c attenuated lung ischemia–reperfusion injury via MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes (PMID 40403491).

Antioxidant and inflammasome pathways. A 2025 study in Free Radical Biology & Medicine reported that MOTS-c attenuated mitochondrial dysfunction, pyroptosis and cartilage degradation in osteoarthritis models through an Nrf2-dependent mechanism (PMID 41043625).

Ubiquitin-pathway effects in cancer models. A 2024 paper in Advanced Science reported that MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination (PMID 39321430).

Limits of the evidence in Module 2

These mechanisms were characterised in different tissues, species and disease models, and they are not obviously one mechanism. CK2 binding in muscle, MYH9-dependent nuclear translocation in lung, and Nrf2 signalling in cartilage may or may not describe the same underlying biology. Mechanistic plausibility is not evidence of clinical effect, and none of these pathway papers measured a patient-level outcome.

Module 3 — Reported outcomes by study

The table below summarises the model, endpoint and reported direction of effect for the studies cited in this course. It is a description of what researchers reported, not a claim about what MOTS-c does in humans.

Metabolic endpoints in more detail

Metabolism is the most-replicated theme. The 2015 Cell Metabolism paper reported that MOTS-c reduced obesity and insulin resistance in mice (PMID 25738459), and a 2022 Pharmacological Research study reported relief of hyperglycemia and insulin resistance in a gestational diabetes mellitus model (PMID 34798268). A 2025 Experimental & Molecular Medicine paper extended the theme to pancreatic islets, reporting that MOTS-c prevented islet cell senescence and delayed diabetes in a preclinical model (PMID 40855115).

Musculoskeletal endpoints in more detail

A 2022 Peptides report found that MOTS-c promoted muscle differentiation in vitro (PMID 35842023), while a 2024 paper in the American Journal of Physiology — Endocrinology and Metabolism reported that MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (PMID 38170165). The 2024 iScience CK2 paper offered a molecular explanation for muscle effects (PMID 39559755).

Limits of the evidence in Module 3

Every outcome above came from cells, rodents or disease models — not from randomised controlled trials in people. Positive findings in an immobilisation model or a xenograft do not establish benefit, and none of these papers promised one. Publication bias also matters: mechanistic peptide fields tend to publish confirmatory results, so the absence of neutral or negative studies in a citation list is not evidence that none exist.

Module 4 — MOTS-c Side Effects: What Studies Report

This module reports what the published literature does and does not say about harms. It is not a safety assurance.

Preclinical reports rarely centre on toxicity. The studies cited here were designed around efficacy endpoints in disease models rather than formal toxicology. The 2015 Cell Metabolism paper reported metabolic improvements in treated mice without describing MOTS-c as a toxic agent in that setting (PMID 25738459), and the 2022 gestational diabetes study likewise reported glycaemic effects as its primary outcome (PMID 34798268). Absence of reported adverse events in an efficacy paper is not the same as a demonstrated safety profile.

Reviews acknowledge the safety gap. The 2023 Frontiers in Endocrinology review discussed MOTS-c as a candidate for therapeutic exploitation while framing the field as early-stage, which is the relevant context for any safety question (PMID 36761202).

Biologically plausible concerns raised by the mechanism literature. Because MOTS-c has been reported to act on broad regulatory systems — CK2 activation in muscle (PMID 39559755), Nrf2-dependent antioxidant signalling in cartilage (PMID 41043625), and ubiquitin-pathway modulation in ovarian cancer cells (PMID 39321430) — the same breadth that makes it interesting also means off-target effects in untested tissues cannot be excluded from the published data.

Limits of the evidence in Module 4

There is no published catalogue of adverse events for MOTS-c comparable to a drug label. No long-term rodent carcinogenicity, reproductive toxicology, immunogenicity or drug-interaction dataset appears in the verified literature summarised here. Anecdotal reports circulating outside peer review are not evidence and are not summarised on this page.

Module 5 — Pharmacokinetics where data exist

Pharmacokinetics is the weakest module of this course, and honestly so. The papers cited here focused on pharmacodynamics — what happened to a tissue or an endpoint — rather than on absorption, distribution, metabolism and excretion in humans.

What can be said from the literature. MOTS-c is a short peptide, and studies delivered it parenterally in animals or directly to cells rather than orally; the 2015 founding study established injected administration in mice as the working model for the field (PMID 25738459). Mechanistic work describing nuclear translocation, such as the 2025 MYH9-dependent lung injury study, implies intracellular access in the tissues examined (PMID 40403491). The 2023 review surveyed the therapeutic-exploitation question, which includes delivery challenges typical of peptides (PMID 36761202).

Limits of the evidence in Module 5

No human half-life, bioavailability, clearance route or dose-proportionality figure is available from the studies summarised here. Any number quoted elsewhere as a human half-life for MOTS-c should be traced to a primary source before it is believed. Because doses in these papers were model- and route-specific, they are not reproduced here as if they were transferable quantities.

Module 6 — Regulatory status, stated factually

• No approved product. MOTS-c is not an approved drug in the United States, the European Union, the United Kingdom or other major jurisdictions. There is no FDA-approved MOTS-c medicine and no established indication.
• Research-use-only material. Synthetic MOTS-c is generally distributed as a research chemical labelled "for research use only — not for human consumption." That label is a regulatory status, not a quality guarantee; RUO material is not manufactured to pharmaceutical standards and its identity and purity are not independently verified as a drug product would be.
• Compounding. In the United States, compounding pharmacies may prepare drugs from bulk substances only where those substances meet specific statutory criteria. Peptides lacking an approved product, a USP monograph or eligible-list status generally fall outside what 503A and 503B facilities may lawfully compound, and FDA has placed a number of peptide substances under review in this context.
• Sport. Athletes should note that mitochondrial-derived and metabolic-modulating peptides may fall under anti-doping prohibitions depending on how the relevant code classifies them; governing-body rules are the authoritative source.

This section is a factual summary of regulatory categories and is not legal advice; rules differ by country and by state, and change over time.

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and time-sensitive. Nothing about regulatory classification speaks to whether MOTS-c works; a compound can be unapproved and interesting, or unapproved and useless, and the label does not distinguish them.

What the studies did not test

Drawing the boundary explicitly is the most useful thing this course can do:

1. Healthy human volunteers. The cited literature examined disease models — obesity, gestational diabetes, immobilisation atrophy, ischemia–reperfusion, osteoarthritis, HBV infection, ovarian cancer. None tested MOTS-c for performance, longevity or body composition in healthy people.
2. Long-term exposure. No chronic-dosing safety study in humans appears in this evidence base.
3. Interactions. No published interaction data with common medications such as metformin, insulin, statins or GLP-1 receptor agonists appear in these papers.
4. Special populations. Although a gestational diabetes model was studied in animals (PMID 34798268), that is an animal model and not evidence in pregnant humans; paediatric and older-adult human data are absent.
5. Comparative effectiveness. No study cited here compared MOTS-c against an established therapy for any condition.
6. Product quality. No cited study evaluated the identity, purity or sterility of material sold outside research supply chains.

Readers with questions about metabolic health, muscle loss, joint disease or any condition mentioned above should raise them with a licensed clinician, who can weigh evidence against an individual medical history. This page summarises published research; it does not recommend, endorse or describe use of any substance.

References

• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology: Endocrinology and Metabolism, 2024)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Experimental & Molecular Medicine, 2025)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes (Redox Biology, 2025)
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism (Free Radical Biology & Medicine, 2025)